Neovacs is a French biotechnology company that focuses on developing innovative treatments for autoimmune diseases through its proprietary Kinoid technology. This technology involves creating therapeutic vaccines that stimulate the immune system to produce natural polyclonal antibodies against specific cytokines responsible for disease pathology. For instance, in the case of lupus, Neovacs has developed Kinoids that target interferon alpha (IFNα), while in asthma, the Kinoids are designed to generate antibodies against interleukin-4 (IL-4) and interleukin-13 (IL-13). By combining these targeted cytokines with a carrier protein, the Kinoids become immunogenic, allowing for a more effective neutralization of the cytokines that contribute to disease symptoms.

In addition to its research and development efforts, Neovacs also engages in investment activities, supporting high-potential biotech and medtech companies. The company has established an external project evaluation committee to identify and invest in innovative products and medical devices. Neovacs actively publishes its research findings in peer-reviewed journals and participates in international scientific conferences, showcasing its advancements in the field of immunotherapy and its commitment to addressing autoimmune diseases through innovative therapeutic approaches.

France

Neovacs is a French biotechnology company that develops products and invests in innovative companies in the biotech and life sciences sectors.

Neovacs

Company Details